Advisors Asset Management Inc. Purchases 211,779 Shares of Johnson & Johnson $JNJ

Johnson & Johnson logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Advisors Asset Management opened a Johnson & Johnson position, buying 211,779 shares in the third quarter, valued at approximately $56.1 million. Institutional investors own 69.55% of the stock.
  • Johnson & Johnson beat quarterly EPS estimates, reporting $2.59 per share versus $2.53 expected; revenue rose 5.9% year over year to $25.40 billion. The company forecast FY 2026 EPS of $11.05–$11.15.
  • Analysts give the stock a consensus “Moderate Buy” rating, with an average price target of $275.92. The company also announced a quarterly dividend of $1.34 per share, equivalent to a 2.0% annualized yield.
  • Five stocks to consider instead of Johnson & Johnson.

Advisors Asset Management Inc. purchased a new stake in Johnson & Johnson (NYSE:JNJ - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 211,779 shares of the company's stock, valued at approximately $56,066,000.

Other institutional investors also recently modified their holdings of the company. Jupiter Topco LLC bought a new stake in shares of Johnson & Johnson in the second quarter worth $1,967,399,000. Corient Private Wealth LP boosted its holdings in Johnson & Johnson by 127.3% during the second quarter. Corient Private Wealth LP now owns 6,060,922 shares of the company's stock worth $1,539,292,000 after purchasing an additional 3,393,981 shares during the last quarter. Wellington Management Group LLP grew its position in Johnson & Johnson by 12.5% in the second quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company's stock valued at $5,736,851,000 after purchasing an additional 2,513,321 shares in the last quarter. Amundi grew its position in Johnson & Johnson by 17.5% in the first quarter. Amundi now owns 13,406,820 shares of the company's stock valued at $3,277,163,000 after purchasing an additional 2,001,139 shares in the last quarter. Finally, Fisher Asset Management LLC grew its position in Johnson & Johnson by 11.5% in the third quarter. Fisher Asset Management LLC now owns 14,837,126 shares of the company's stock valued at $3,927,981,000 after purchasing an additional 1,530,070 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

JNJ has been the topic of several analyst reports. Raymond James Financial set a $280.00 price target on shares of Johnson & Johnson in a research report on Monday, August 3rd. Leerink Partners reduced their price objective on shares of Johnson & Johnson from $276.00 to $272.00 and set an "outperform" rating for the company in a research note on Wednesday, October 14th. Weiss Ratings cut Johnson & Johnson from a "buy (b+)" rating to a "buy (b-)" rating in a report on Friday, October 23rd. Wells Fargo & Company lifted their target price on Johnson & Johnson from $275.00 to $287.00 and gave the company an "overweight" rating in a research report on Friday, October 16th. Finally, Sanford C. Bernstein set a $270.00 target price on Johnson & Johnson in a report on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $275.92.

Check Out Our Latest Stock Report on Johnson & Johnson

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $267.02 on Friday. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44. The business's 50 day moving average price is $267.43 and its two-hundred day moving average price is $250.79. The company has a market cap of $642.80 billion, a PE ratio of 40.46, a price-to-earnings-growth ratio of 2.74 and a beta of 0.22. Johnson & Johnson has a twelve month low of $199.90 and a twelve month high of $290.25.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The company had revenue of $25.40 billion during the quarter, compared to analysts' expectations of $25.38 billion. During the same period last year, the firm posted $2.80 earnings per share. The business's revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, analysts predict that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be given a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson's payout ratio is 81.21%.

Insiders Place Their Bets

In other news, EVP Timothy Schmid sold 33,597 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the transaction, the executive vice president directly owned 25,447 shares of the company's stock, valued at $6,991,308.78. This represents a 56.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Elizabeth Forminard sold 13,072 shares of the firm's stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $284.39, for a total transaction of $3,717,546.08. Following the sale, the executive vice president owned 16,994 shares of the company's stock, valued at approximately $4,832,923.66. This represents a 43.48% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.16% of the company's stock.

Top Johnson & Johnson Stories

Investors following JNJ have been watching these stories:

  • Positive Sentiment: Prostate cancer data presented at ESMO were described as “immaculate,” suggesting Johnson & Johnson’s $3.05 billion Halda acquisition is showing clinical promise. The data could strengthen the company’s oncology pipeline, though the program remains subject to further development. Article
  • Positive Sentiment: Johnson & Johnson filed for FDA approval to expand CAPLYTA to bipolar I mania or mixed episodes. Two Phase 3 studies showed symptom improvement versus placebo; approval would add a potential fifth adult indication, but remains uncertain. Article
  • Negative Sentiment: A Louisiana appeals court upheld a multimillion-dollar talc verdict and an increase in damages, adding to potential legal costs and uncertainty. Separately, Pomerantz LLP announced an investigation into investor claims; the announcement is not a finding of wrongdoing. Appeal ruling article Investor investigation notice

About Johnson & Johnson

(Free Report)

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

Further Reading

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Johnson & Johnson Right Now?

Before you consider Johnson & Johnson, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.

While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines